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severe (classic) or mild (nonclassic). Classic forms of CAH are diagnosed in infancy on the basis of neonatal screening tests, whereas nonclassic CAH is usually diagnosed in adolescence or young adulthood [7] . Classic CAH is subdivided into salt-wasting (SW) and simplevirilizing (SV) forms, depending on whether mineralocorticoid synthesis is affected [1, 4] .
Management of CAH presents unique challenges distinct from other forms of adrenal insufficiency. Higher doses of glucocorticoids are required to suppress adrenal androgen synthesis, which can lead to overtreatment and iatrogenic Cushing syndrome [3, 8, 9] . Use of long-acting glucocorticoids in children is avoided because of the risk of growth suppression; hydrocortisone is considered the preferred glucocorticoid in this population [2] . The ideal glucocorticoid for the treatment of adults with CAH is more contentious [10] . Although hydrocortisone in divided doses is a common treatment option, once-or twice-daily preparations of long-acting glucocorticoids are also used, including prednisolone and dexamethasone [1, 2, 4] . Newer preparations of hydrocortisone have also been trialed, including modified-release tablets and continuous subcutaneous hydrocortisone infusions (CSHIs) [11, 12] . Assessment of treatment adequacy remains challenging. The aim of this systematic review and meta-analysis was to review the efficacy of different glucocorticoid regimens in the management of CAH.
Methods

A. Search Strategy
A systematic search of PubMed/Medline and Web of Science was undertaken of articles published up to 25 February 2019. The search terms used were "congenital adrenal hyperplasia", "CAH", "21-hydroxylase deficiency", "steroid regimen", "glucocorticoid regimen", and "glucocorticoid". Studies of all languages and publication dates were included. Articles were screened initially by title and then by abstract for relevance. Full-text review was then undertaken for selected studies. Reference lists of identified articles were then reviewed to identify other relevant studies not retrieved in the database searches. All included and excluded articles were agreed on by all coauthors with reference to the criteria described in the following section.
B. Study Selection and Data Extraction
Studies that compared at least two different types of glucocorticoids in individuals with CAH were included, some of which used baseline glucocorticoid therapy as the comparator. Studies were excluded if only a single type of glucocorticoid was assessed or if results were combined with individuals with other forms of adrenal insufficiency and not expressed separately. Studies were also excluded if glucocorticoid preparations were compared only in terms of glucocorticoid-equivalent dose rather than type of glucocorticoid. Only original research was included (i.e., review articles and editorials were excluded). Meeting abstracts were also excluded.
The following information was extracted from each article: first author, year of publication, number and characteristics of patients and control subjects, types and doses of glucocorticoid regimen used, study design and outcomes [e.g., biochemical tests, weight, height, body mass index (BMI), bone mineral density (BMD)]. All biochemical variables were converted into International System of Units values. Glucocorticoid doses were converted into hydrocortisone-equivalent doses using growth-retarding equivalents (i.e., hydrocortisone 20 mg 5 cortisone acetate 25 mg 5 prednisolone 4 mg 5 dexamethasone 0.25 mg) [8] . Patients receiving cortisone acetate were included in the hydrocortisone treatment group. Any treatment combination with dexamethasone was included in the dexamethasone treatment group. Quality assessment instruments [e.g., the Newcastle-Ottawa scale (www.ohri.ca/ programs/clinical_epidemiology/oxford.asp)] were unable to be applied to most of the studies by virtue of their study design, but the quality of the included studies can be generally appreciated in Table 1 . The Preferred Reporting Items for Systematic Reviews and Metaanalyses guidelines were followed [34] .
C. Statistical Analysis
Mean 6 SD (if normally distributed) or median and interquartile range (25% to 75%) were used. Two groups and continuous variables were analyzed with unpaired t test or MannWhitney rank-sum test if not normally distributed. Three groups were analyzed with one-way ANOVA, or ANOVA on ranks when values were not normally distributed. If exact individual values could not be extracted from the articles or by contacting the authors, approximate values from figures or mean and median values were used. If several articles were from the same cohort, the data were combined. Statistical significance was defined as P , 0.05. All analyses were performed using SigmaStat, version 3.0 for Windows (Systat Software, San Jose, CA).
Results
The systematic search identified 617 articles. Six additional articles were identified from review of reference lists. A total of 612 articles were identified and screened for eligibility after duplicates were removed. In total, 23 studies were included in the qualitative synthesis, with 19 included in the quantitative synthesis (Fig. 1) . The included studies are summarized in Table 1 . The studies assessed a variety of outcome measures. Most of the studies assessed the effect of different glucocorticoid regimens on morning 17OHP levels. Other outcome measures included testosterone and androstenedione (A4) levels, BMI, and BMD. The included studies did not report on clinical signs of hyperandrogenism. Four of the included studies assessed glucose tolerance by measuring Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [11] [12] [13] 33] .
A. Hydrocortisone vs Prednisolone
Twelve of the included studies compared hydrocortisone and prednisolone therapy [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Outcomes assessed included 17OHP and A4 levels, BMI, and BMD. In terms of 17OHP levels, most studies did not find any significant differences between treatment groups. However, Nebesio et al. [22] found that mean 17OHP levels were lower in those individuals treated with hydrocortisone.
Several of the included studies assessed the impact of glucocorticoid treatment regimens on final height [15, 16, 19] . Bonfig et al. [15] found that prednisolone treatment was associated with higher hydrocortisone-equivalent doses and significantly reduced final height when compared with hydrocortisone. In contrast, Caldato et al. [16] found that the ratio of bone age to chronological age was higher in individuals treated with hydrocortisone therapy, suggesting that hydrocortisone is less effective at slowing skeletal maturation. They also found that height SD scores corrected for bone age improved significantly in those individuals treated with 12 months of prednisolone therapy when compared with those treated with hydrocortisone [16] . Leite et al. [19] did not find any difference between hydrocortisone and prednisolone therapy in terms of variation in height SD scores, variation of height SD scores according to bone age, and variation of body mass SD scores.
Falhammar et al. [13] found that hydrocortisone/cortisone acetate were associated with increased values for markers of cardiovascular and metabolic risk compared with prednisolone, including BMI, waist-to-hip ratio, serum insulin during oral glucose tolerance test, total fat mass, and trunk fat mass, despite similar doses of hydrocortisone equivalents. Prednisolone was shown in two studies to be associated with higher rates of osteoporosis and fractures [17, 21] .
B. Dexamethasone vs Hydrocortisone and/or Prednisolone
Nine of the identified studies evaluated the use of dexamethasone compared with hydrocortisone and/or prednisolone [20] [21] [22] [23] [24] [25] [26] [27] , and three additional studies described only a single Same cohort but measuring different outcomes, all data were combined in the analysis. One of the patients was on dexamethasone and was therefore excluded in the comparisons between hydrocortisone and prednisolone but was included in the meta-analysis. patient receiving dexamethasone [13, 17, 18] . As expected, dexamethasone was associated with significantly greater adrenal suppression [20, [22] [23] [24] [25] 27] . Dexamethasone treatment was associated with lower BMD than hydrocortisone or prednisolone in one study [21] , but slightly better femoral neck T-score in another study [20] . 
C. Hydrocortisone vs Modified-Release Hydrocortisone
Two studies compared conventional hydrocortisone tablets with modified-release hydrocortisone. Verma et al. [28] compared once-daily modified-release hydrocortisone (MR-HC) with thrice-daily hydrocortisone. The study found that 8:00 AM 17OHP levels were significantly lower in the MR-HC group than in the hydrocortisone group, whereas afternoon 17OHP levels were significantly higher. Mallappa et al. [11] compared twice-daily MR-HC with subjects' usual glucocorticoid treatment and found that 17OHP and A4 levels were significantly lower in the MR-HC group. There was no significant difference in HOMA-IR, BMI, or quality of life between groups. Because of the small number of patients treated with MR-HC, these data were not included in the meta-analysis.
D. Continuous Subcutaneous Hydrocortisone Infusion
Four studies assessed the use of CSHI in the management of CAH [12, [29] [30] [31] . Three of these studies were case reports of individual patients [29] [30] [31] ; the fourth study included eight subjects and compared CSHI with subjects' preexisting glucocorticoid regimen [12] . All four studies reported a reduction in 17OHP levels with CSHI treatment compared with baseline. Nella et al. [12] assessed changes in metabolic indices and found that weight increased with CSHI compared with individuals' baseline glucocorticoid regimens, whereas other indices did not change (including HOMA-IR; levels of C-peptide, leptin, C-reactive protein, and lipids; and waist-to-hip ratio). As with MR-HC, the number of patients treated with CSHI was small and as such, the data were not included in the meta-analysis.
E. IV Hydrocortisone Infusion
One study of two subjects with CAH evaluated the use of IV hydrocortisone [32] . Subjects were only treated for 24 hours. Morning 17OHP levels were reduced in subjects treated with IV hydrocortisone compared with those receiving oral hydrocortisone.
E.1. Quality of life measures
Five of the 23 studies examined the influence of glucocorticoid regimens on quality of life [11, 12, 18, 20, 30] . Mallappa et al. [11] found no difference between subjects' baseline glucocorticoid regimen and MR-HC in terms of the 36-item short-form health survey (SF-36), health-related quality of life in Addison disease, and global fatigue index scores. Falhammar et al. [18] compared psychological general well-being (PGWB) scores and found no difference between control subjects and subjects with CAH treated with prednisolone. However, individuals with CAH treated with hydrocortisone or cortisone acetate had significantly lower PGWB scores in most areas, compared with control subjects [18] . Patients with poorly controlled CAH also had significantly better PGWB scores compared with those who were over treated [18] . In contrast, SF-36 scores were significantly lower in individuals treated with prednisolone or dexamethasone compared with those in the CaHASE cohort treated with hydrocortisone [20] . CSHI was associated with improved SF-36 and global fatigue index scores in two studies [12, 30] .
E.2. Bone mineral density
Four of the included studies assessed the influence of different glucocorticoid regimens on BMD [11, 17, 20, 21] . Falhammar et al. [17] reported that patients with CAH treated with prednisolone had significantly lower BMD than control subjects, whereas subjects treated with hydrocortisone or cortisone acetate did not have significantly different BMD compared with control subjects [17] . Mallappa et al. [11] found that after 6 months of treatment with MR-HC, whole-body BMD was significantly lower when compared with baseline glucocorticoid treatment. Han et al. [20] found that dexamethasone was associated with higher femoral BMD compared with hydrocortisone or prednisolone, but the number of patients who had BMD measurement was low. In contrast, Jääskeläinen et al. [21] found that subjects treated with dexamethasone or prednisolone had decreased BMD compared with subjects treated with hydrocortisone.
E.3. Meta-analysis
Of the 23 studies, 16 presented results for subjects treated with hydrocortisone and were included in the meta-analysis. In total, 172 subjects received hydrocortisone or cortisone acetate, with 192 results available (20 of the subjects were included twice, either owing to subjects receiving hydrocortisone at two different evening time points or to subjects being given hydrocortisone for a discrete period, followed by cortisone acetate [14, 25] . Ten of the 23 studies included results for subjects receiving prednisolone, with data for 178 individuals. Eleven of the 23 studies presented results for subjects taking dexamethasone therapy, with data for 79 individuals included in the meta-analysis. There was no significant difference in the age of subjects treated with dexamethasone, prednisolone, or hydrocortisone (P 5 0.102). Subjects treated with dexamethasone had significantly higher hydrocortisone-equivalent doses compared with those treated with prednisolone or hydrocortisone [18.4 (15. 17OHP levels were significantly lower in subjects receiving dexamethasone, compared with those taking hydrocortisone or prednisolone (Fig. 2a) . A4 levels were also significantly lower in individuals receiving dexamethasone, compared with prednisolone or hydrocortisone (Fig. 2b) .
Subjects taking dexamethasone had significantly higher BMI than those taking prednisolone or hydrocortisone (Fig. 3a, only adults included) . Lumbar spine Z-scores were significantly lower in subjects treated with dexamethasone compared with those treated with hydrocortisone or prednisolone (Fig. 3b) . Femoral neck Z-scores were also significantly lower in subjects treated with dexamethasone (Fig. 3c) .
Discussion
This is a systematic review and meta-analysis of glucocorticoid regimens in the management of CAH. Although current guidelines recommend the use of hydrocortisone in children with CAH, there is no consensus about the appropriate glucocorticoid regimen in adult patients [1, 2] . Patients are often transitioned to therapy with long-acting glucocorticoids on reaching adulthood, which allow less-frequent dosing and improved compliance [35] . Moreover, CAH poses unique management issues, distinct from other forms of adrenal insufficiency. The management of CAH requires a balance between glucocorticoid replacement and adrenal hormone suppression [2] . To achieve the latter, individuals often require supraphysiological doses of glucocorticoids. This in turn leads to detrimental effects on BMD, final height, and BMI. We found that regimens based on hydrocortisone or prednisolone have similar benefits and adverse effects, whereas a regimen based on dexamethasone was more effective in adrenal hormone suppression but also displayed more adverse effects.
The frequency of particular glucocorticoid regimens varies between cohorts [3, 8, 36] . Adult patients may be prescribed hydrocortisone, prednisolone, dexamethasone, or a combination of glucocorticoid preparations. Most of included studies were retrospective; therefore, it is important to acknowledge that the choice of therapy may have been dictated by patient factors and prone to bias. For instance, issues with compliance or difficult-to-control hyperandrogenism may have led to use of longer-acting glucocorticoids, such as prednisolone or dexamethasone. Sixteen of the included studies assessed oral hydrocortisone as a comparator, 12 of which also evaluated prednisolone therapy. Perhaps surprisingly, there was no significant difference in 17OHP levels between hydrocortisone and prednisolone treatment groups in the meta-analysis, and one of the studies actually showed lower 17OHP levels in the hydrocortisone group [22] . Caldato et al. [16] argued that the lack of difference in 17OHP levels seen in their cohort supported the use of once-daily prednisolone therapy to facilitate compliance. Moreover, Falhammar et al. [18] found that individuals treated with hydrocortisone/cortisone acetate had significantly lower PGWB scores than did control subjects, whereas scores of patients treated with prednisolone were not significantly different from those of control subjects. However, the diurnal 17OHP curves on dried blood spots were similar between those treated with hydrocortisone/cortisone acetate and those treated with prednisolone [17] . By contrast, dexamethasone therapy led to significantly greater adrenal suppression than other glucocorticoid regimens [20, [22] [23] [24] [25] 27] . This greater adrenal suppression was at the cost of reduced BMD in the form of Z-scores in the meta-analysis, although Han et al. [20] found higher femoral neck T-scores in patients treated with dexamethasone; however, the number of individuals having dual-energy X-ray absorptiometry was relatively low.
The doses and dosing schedules of glucocorticoids also vary widely between adult patients with CAH [3] . Hydrocortisone is typically administered thrice daily, prednisolone twice daily, and dexamethasone once daily [1] [2] [3] [4] . The adjustment of glucocorticoid doses is usually made with reference to morning 17OHP and A4 levels [2] . There are no specific treatment targets for the management of CAH, although it is recommended that morning 17OHP levels should be slightly elevated and A4 levels should be in the normal range [2, 7, 35] . Although 17OHP and androgen levels usually correlate, 17OHP is vastly more variable and may be present at 100 to 1000 times higher levels than androgens [35] . Thus, A4 levels can be normal in the setting of elevated 17OHP levels. To overcome this disparity, diurnal curves using dried blood spots measuring 17OHP can be used, but such curves are currently only available in a few centers [1, 7] . Whether the recently rediscovered 11-oxyandrogens can be used in biochemical monitoring and predicting long-term outcomes remains to be seen [37] . We found that individuals treated with dexamethasone received significantly higher hydrocortisoneequivalent doses than those treated with hydrocortisone or prednisolone, which was further supported by the lower morning 17OHP and A4 levels. It is important to note that there is uncertainty about the appropriate conversion factor of dexamethasone to hydrocortisoneequivalent doses, and a higher potency of dexamethasone has been suggested more recently [33, 38] . If prescribed, dexamethasone doses should be lower than those used in the included studies and probably lower than has been previously suggested.
Many of the long-term complications of CAH are related to excessive glucocorticoid exposure. Arlt et al. [3] found that 52% of female patients with 21-hydroxylase deficiency in a UK cohort were obese, and 28% had insulin resistance. A Swedish cohort of 588 patients with CAH had higher rates of obesity, diabetes, hypertension, and hyperlipidemia than did control subjects [9] . Thus, patients with CAH should be prescribed the lowest possible glucocorticoid dose to prevent symptoms and signs of both hyperandrogenism and adrenal crisis [39] . The choice of glucocorticoid preparation is likely to be guided by the patient and health care provider's preferences and previous experience. However, dexamethasone should probably be avoided where possible and reserved for selected cases (e.g., patients with poor compliance).
The difficulties associated with CAH management have led to investigation of other treatment options, including MR-HC tablets and CSHI. Both regimens seem promising, but more studies are needed. However, CSHI requires extra resources and its use will probably not be widespread. Another approach is bilateral adrenalectomy, which obviates the requirement for hypothalamic-pituitary-adrenal axis suppression, such that patients require replacement doses only. A recent systematic review and meta-analysis of bilateral adrenalectomy in the management of CAH found that such surgery was a reasonable treatment option in a carefully selected cohort of patients [40] . However, the Endocrine Society Clinical Practice Guideline recommends against adrenalectomy, because of the significant surgical risk and increased risk of adrenal crisis [2] .
Our study has a number of limitations. First, we did not have access to all of the individual patient data in the included studies, such that some data were approximated from figures or graphs, or from mean values. Some studies could not be included in the meta-analysis for this reason. Secondly, the studies included were heterogeneous, mostly retrospective, and included patients of varying ages with quite diverse methodology. In addition, the number of patients treated with certain regimens was somewhat limited, especially in the MR-HC and CSHI groups. Not all outcomes were analyzed in all patients. We could not separate the results for female and male patients, because in most studies, the results of different glucocorticoid regimens were not separated by sex. Individuals' glucocorticoid doses were often not presented. To evaluate the advantages and disadvantages of the different glucocorticoid regimens more rigorously, a study would need to do the following: (i) check that baseline conditions including age, sex, BMI, BMD, and glucose tolerance, are similar in all groups of subjects; (ii) use similar hydrocortisone-equivalent doses in each regimen; (iii) investigate all positive and negative effects of each regimen. Moreover, it should be randomized. Unfortunately, such a study would be difficult to perform, owing to the low prevalence of CAH and the long follow-up needed.
In conclusion, we found in this systematic review and meta-analysis that dexamethasone therapy is associated with greater adrenal androgen suppression, as well as more adverse effects, including higher BMI and lower BMD. In contrast, we did not find significant differences between hydrocortisone and prednisolone therapy in terms of adrenal hormone levels or adverse effects. However, individuals treated with dexamethasone received higher hydrocortisone-equivalent doses than those treated with hydrocortisone or prednisolone. These results suggest that dexamethasone therapy may not be the first choice, and if used, a lower dose should be considered. The choice of therapy between hydrocortisone and prednisolone therapy in adult patients will depend on individual patient factors and physician judgement.
